Article citationsMore>>

Hamada, N., Kuwano, K., Yamada, M., Hagimoto, N., Hiasa, K., Egashira, K., Nakashima, N., Maeyama, T., Yoshimi, M. and Nakanishi, Y. (2005) Anti-vascular endothelial growth factor gene therapy attenuates lung injury and fibrosis in mice. Journal of Immunology, 175, 1224-1231. http://www.jimmunol.org/content/175/2/1224.full

has been cited by the following article:

• TITLE: Biomarkers and atrial fibrillation: A new paradigm for assessing the progression of left atrial endocardial remodelling

  AUTHORS: Philippe Chevalier, Alina Scridon

  KEYWORDS: Atrial Fibrillation; Biomarkers; Progression

  JOURNAL NAME: Open Journal of Clinical Diagnostics, Vol.2 No.2, June 19, 2012

  ABSTRACT: Atrial fibrillation is a heterogeneous disorder that is usually characterized by paroxysmal onset, particularly in patients without structural heart disease. Defining biological markers of atrial remodelling would help identify patients at high risk who would benefit most from prophylactic treatment and careful monitoring. Biomarkers of atrial fibrillation progression would be helpful for following patients that present with asymptomatic atrial fibrillation. Notably, the roles of such markers in the pathophysiology of atrial fibrillation must be determined. Some markers may indicate the presence, complications or progression of the disease, while others may be involved in key pathological processes and thus represent novel therapeutic targets. Although a number of markers have been reported as potential predictors of paroxysmal atrial fibrillation progression towards persistent arrhythmia, their usefulness and clinical value need further validation. This report reviews several newly identified markers of atrial fibrillation progression.